Establishment of CYP2D6 reference samples by multiple validated genotyping platforms.

Establishment of CYP2D6 reference samples by multiple validated genotyping platforms.
复制标题

DOI:
10.1038/tpj.2014.27
复制
发表时间:
2014-12
期刊:
The pharmacogenomics journal
影响因子:
--
通讯作者:
O'Donnell PH
O'Donnell PH
中科院分区:
其他
文献类型:
--
作者:
Fang H;Liu X;Ramírez J;Choudhury N;Kubo M;Im HK;Konkashbaev A;Cox NJ;Ratain MJ;Nakamura Y;O'Donnell PH

文献摘要

参考文献

被引文献

相似文献

细胞色素 P450 2D6(细胞色素 P450、家族 2、亚家族 D、多肽 6 或 CYP2D6)是一种高度多态性的药物代谢酶,参与四分之一最常用处方药物的代谢。在这里,我们应用了多种基因分型方法和桑格测序来为 48 个 HapMap 样本分配精确且可重复的 CYP2D6 基因型,包括拷贝数。此外,通过使用 N-去甲基他莫昔芬形成的内多昔芬作为感兴趣的表型来分析一组 50 个人类肝微粒体,我们观察到 CYP2D6 基因型指定的活性评分与内多昔芬形成率之间存在显着的正相关性(通过 Rank 相关性检验,rs = 0.68,P = 5.3 ×10−8),这证实了基因型-表型 来自我们的基因分型方法的预测。将来,这 48 个公开的 HapMap 样本以多个经证实的 CYP2D6 基因分型平台为特征,可以作为其他 CYP2D6 基因分型项目和临床药物基因组测试实施项目的测定开发、验证、质量控制和能力验证的参考资源。
Cytochrome P450 2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6, or CYP2D6), a highly polymorphic drug metabolizing enzyme, is involved in the metabolism of one quarter of the most commonly prescribed medications. Here, we have applied multiple genotyping methods and Sanger sequencing to assign precise and reproducible CYP2D6 genotypes, including copy numbers, for 48 HapMap samples. Furthermore, by analyzing a set of 50 human liver microsomes using endoxifen formation from N-desmethyl-tamoxifen as the phenotype of interest, we observed a significant positive correlation between CYP2D6 genotype-assigned activity score and endoxifen formation rate (rs = 0.68 by Rank correlation test, P = 5.3 ×10−8), which corroborated the genotype-phenotype prediction derived from our genotyping methodologies. In the future, these 48 publicly available HapMap samples characterized by multiple substantiated CYP2D6 genotyping platforms could serve as a reference resource for assay development, validation, quality control, and proficiency testing for other CYP2D6 genotyping projects, and for programs pursuing clinical pharmacogenomic testing implementation.
来自1,092个人基因组的遗传变异的综合图。
DOI: 10.1038/nature11632
发表时间: 2012-11-01
期刊: Nature
影响因子: 64.8
作者:
通讯作者: --
DOI: 10.1038/clpt.2011.287
发表时间: 2012-02-01
影响因子: 6.7
作者:
Crews, K. R.;Gaedigk, A.;Skaar, T. C.
通讯作者: Skaar, T. C.
DOI: 10.3109/09540261.2013.825581
发表时间: 2013-10-01
影响因子: 2.8
作者:
Gaedigk, Andrea
通讯作者: Gaedigk, Andrea
DOI: 10.2217/pgs.13.160
发表时间: 2013-11-01
期刊: PHARMACOGENOMICS
影响因子: 2.1
作者:
Qian, Jian-Chang;Xu, Xin-Min;Cai, Jian-Ping
通讯作者: Cai, Jian-Ping
DOI: 10.1373/clinchem.2009.123620
发表时间: 2009-08-01
期刊: CLINICAL CHEMISTRY
影响因子: 9.3
作者:
Hosono, Naoya;Kato, Mamoru;Kubo, Michiaki
通讯作者: Kubo, Michiaki